DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1746)

Venous Thromboembolism | Unmet Need | Detailed, Expanded Analysis (US & EU)

Venous Thromboembolism | Unmet Need | Detailed, Expanded Analysis (US & EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

MARKET OUTLOOK

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the NOACs signifies an important milestone for the treatment and secondary prophylaxis of VTE, there are still some areas of unmet need that remain underserved in this patient population. This report examines current treatment performance against treatment goals in the treatment and secondary prophylaxis of DVT and PE from the perspective of emergency room physicians and hematologists. This report also offers insight from these physicians on existing unmet needs for DVT and PE, while our target product profile conjoint simulator demonstrates how various attributes influence these physicians’ prescribing decisions.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for VTE?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for VTE?
  • What are the prevailing areas of unmet need and opportunity in VTE?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European emergency room physicians and hematologists for a hypothetical new VTE drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered:United States, France, Germany, and United Kingdom.

Primary research: Survey of 60 U.S. and 31 European emergency room physicians and hematologists fielded in May 2018.

Key companies: Bayer, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, and Janssen Pharmaceuticals.

Key drugs: Pradaxa, Xarelto, Eliquis, and Savaysa/Lixiana.

Already a Client? Log in to access this report.

  • Pub Date: July 2018
  • Author(s): Shreya Saxena, MBA
  • Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.

Become a DRG client

Recent reports:
You may also be interested in: